SynthesisFrontiers in pharmacology2024
Network meta-analysis of integrated traditional Chinese and Western medicine in the treatment of Sjogren's syndrome.
Synthesis in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Shengjiangsan Upregulates miR-328-3p to Inhibit MAP3K9 in the Treatment of Sjogren Disease: A Bioinformatics Analysis.Journal of inflammation research · 2026Article
- Exploring the immunomodulatory mechanism of total glucosides of paeony on Sjögren's syndrome dry eye disease based on the "gut-eye axis" pathway.International ophthalmology · 2025Article
- Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate efficacy and safety of traditional Chinese medicine (TCM) combined with Western medicine in treatment of Sjogren's syndrome (SS). Methods: CNKI, WanFang, VIP, CBM, Sinomed, PubMed, Embase, and Web of Science were searched to collect randomized controlled trials (RCTs) of TCM combined with conventional western medicine (CWM) in treating SS from the time of their estalishment to May 2023. The researchers independently screened the literature and extracted data for quality evaluation. Analyses were performed using Review Manager (version 5.4) and R-4.3.1. Results: A total of 66 RCTs were included, with a sample size of 5,052, involving four kinds of TCM (total glucosides of paeony capsules, tripterygium glycosides tablet, Xinfeng capsule and Jinju Qingrun capsule) and three kinds of CWM(hydroxychloroquine sulfate, Iguratimod and glucocorticoid). The network meta-analysis results showed that IGU + HCQ + TGP ranked the highest in reducing ESR and IgG and improving the Schirmer test when the three drugs were combined. When the two drugs are combined, IGU + GC and TGT + TGP are good choices for reducing erythrocyte sedimentation rate (ESR) and Immunoglobulin G (IgG). Although TGP + HCQ vs. HCQ had the most studies, TGP combined with HCQ did not rank high in each outcome indicator. It is recommended to use TGT and XFG in decreasing ESR and IgG for a single drug. JJQR have an advantageous role in relieving xerostomia and dry eyes. Conclusion: TCM combined with CWM has a very significant effect on treating SS compared with CWM alone. According to the network meta-analysis, the best intervention measures of different TCMs for different outcome indicators were obtained. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42023451845].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.